Forskning ved Københavns Universitet - Københavns Universitet

Forside

B-lymfocytdepletring og andre biologiske behandlingsmuligheder ved Graves' oftalmopatiTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Publikation: Bidrag til tidsskriftTidsskriftartikel

The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO
Udgivelsesdato: 2008/6/9
OriginalsprogDansk
TidsskriftUgeskrift for læger
Vol/bind170
Udgave nummer24
Sider (fra-til)2128-2130
Antal sider2
ISSN0041-5782
StatusUdgivet - 2008

ID: 14148866